前往化源商城

Antiviral Research 2015-08-01

Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity.

Xue-jun Wang, Wei Hu, Ting-yu Zhang, Ying-ying Mao, Nan-nan Liu, Sheng-qi Wang

文献索引:Antiviral Res. 120 , 140-6, (2015)

全文:HTML全文

摘要

The liver-specific Na(+)-dependent taurocholate cotransporting polypeptide (NTCP) was recently identified as an entry receptor for hepatitis B virus (HBV) hepatotropic infection. In this study, an NTCP-overexpressing HepG2 cell line named HepG2.N9 susceptible to HBV infection was established using transcription activator-like effector nucleases (TALEN) technology. Using this cell line, irbesartan, the new NTCP-interfering molecule reported recently, was demonstrated here to effectively inhibit HBV infection with an IC50 of 3.3μM for hepatitis B e antigen (HBeAg) expression and exhibited no obvious cytotoxicity up to 1000μM. Irbesartan suppressed HBV uptake weakly but inhibited HBV covalently closed circular DNA (cccDNA) formation efficiently at physiological temperature. These results suggested that irbesartan targeted HBV infection at a post-uptake prior to cccDNA formation step such as the cell membrane fusion. Based on these findings, irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, could be a potential candidate for treatment of HBV infection although further in vivo experiments are required. Copyright © 2015 Elsevier B.V. All rights reserved.

相关化合物

结构式 名称/CAS号 全部文献
环孢霉素A 结构式 环孢霉素A
CAS:59865-13-3
辛伐他汀,斯伐他汀 结构式 辛伐他汀,斯伐他汀
CAS:79902-63-9
利托那韦 结构式 利托那韦
CAS:155213-67-5
4',6-二脒基-2-苯基吲哚二盐酸盐 结构式 4',6-二脒基-2-苯基吲哚二盐酸盐
CAS:28718-90-3
甲磺酸多沙唑嗪 结构式 甲磺酸多沙唑嗪
CAS:77883-43-3
乙二胺四乙酸 结构式 乙二胺四乙酸
CAS:60-00-4
厄贝沙坦 结构式 厄贝沙坦
CAS:138402-11-6